(Q37799413)

23 August 2017

title

Safety evaluation of biological drugs: what are toxicology studies in primates telling us? (English)

1 reference

23 August 2017

Paul Baldrick

1

1 reference

23 August 2017

language of work or name

English

0 references

publication date

16 October 2010

1 reference

Regulatory Toxicology and Pharmacology

23 August 2017

published in

1 reference

23 August 2017

volume

59

1 reference

23 August 2017

issue

2

1 reference

23 August 2017

page(s)

227-236

1 reference

Safety evaluation to support First-In-Man investigations II: toxicology studies

23 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2010.10.005

Preclinical assessment of anti-CD40 Mab 5D12 in cynomolgus monkeys.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2010.10.005

Safety and immunotoxicity assessment of immunomodulatory monoclonal antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2010.10.005

Nonclinical safety, pharmacokinetics, and pharmacodynamics of atacicept

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2010.10.005

The future of non-human primate use in mAb development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2010.10.005

Duration of chronic toxicity studies for biotechnology-derived pharmaceuticals: is 6 months still appropriate?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2010.10.005

Immunogenicity of protein therapeutics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2010.10.005

Chronic administration of belimumab, a BLyS antagonist, decreases tissue and peripheral blood B-lymphocyte populations in cynomolgus monkeys: pharmacokinetic, pharmacodynamic, and toxicologic effects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2010.10.005

Preclinical efficacy and safety of pascolizumab (SB 240683): a humanized anti-interleukin-4 antibody with therapeutic potential in asthma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2010.10.005

Management and preparedness for infusion and hypersensitivity reactions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2010.10.005

Practical considerations for nonclinical safety evaluation of therapeutic monoclonal antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2010.10.005

Absence of adverse effects in cynomolgus macaques treated with CNTO 95, a fully human anti-alphav integrin monoclonal antibody, despite widespread tissue binding

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2010.10.005

Preclinical Safety and Pharmacology of an Anti-Human Interleukin-13 Monoclonal Antibody in Normal Macaques and in Macaques with Allergic Asthma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2010.10.005

Immunogenicity of biologically-derived therapeutics: assessment and interpretation of nonclinical safety studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2010.10.005

Preclinical safety evaluation of recombinant human interleukin-10.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2010.10.005

Preclinical safety evaluation of rhuMAbVEGF, an antiangiogenic humanized monoclonal antibody

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2010.10.005

Preclinical and clinical safety of monoclonal antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2010.10.005

Immunogenicity of biopharmaceuticals in laboratory animals

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2010.10.005

10.1016/J.YRTPH.2010.10.005

7 January 2021

Identifiers

DOI

1 reference

23 August 2017

1 reference